[ad_1]
Pfizer, which competes with its competitors for its initial gene therapies, is turning its production efforts into overdrive. The company will inject an additional $ 500 million into a manufacturing plant in North Carolina and hire an additional 300 workers.
The investment of half a billion dollars adds to the $ 100 million committed to the Sanford, North Carolina, project in 2017, Pfizer said today. The facility will support its gene therapy work in the Pfizer Chapel Hill and Kit Creek research and development facilities. He says the largest plant will add to its clinical and commercial scale production capabilities for its work on potential genetic remedies using recombinant adeno-associated viral vectors.
RELATED: Pfizer Commits $ 100 Million for Gene Plant in North Carolina
"We are excited to build this new, state-of-the-art facility in Sanford as it will enable us to develop new methods to provide transformative therapies to patients," said Angela Hwang, president of Pfizer Biopharmaceuticals, in a statement.
Pfizer started the project a few years ago, announcing the expansion of an 11,000-square-foot plant in Sanford, acquired during the purchase of Bamboo Therapeutics biotechnological gene therapies. At that time, it was expected that the expansion would accompany about 40 jobs. The 300 hires it plans to make will take Pfizer's workforce to about 650 people in Sanford, where workers are also manufacturing components for the company's vaccine portfolio.
RELATED: New Pfizer boost data, Sangamo hemophilia A gene therapy
Pfizer has several gene therapy programs through which it conducts. His partner, Sangamo Therapeutics, shared last month a positive update on the sustainability of responses to their gene therapy for hemophilia A. The insight prompts those who believe it will outpace other strengths including SPK-8011 from Spark Therapeutics and BioMarin's Valrox. This month, BioMarin has abandoned the development of a lower dose of its valrox treatment in order to be able to apply its applications to regulators by the end of the year.
Pfizer also published data this summer on its gene therapy for Duchenne muscular dystrophy. This early clinical update showed that one of the first six people to receive treatment had been hospitalized for acute kidney injury. The results have led analysts to give the advantage to the competing efforts of Sarepta Therapeutics.
[ad_2]
Source link